News & Updates

Treatment with ripretinib provides a prolonged clinical and radiological benefit in patients with advanced gastrointestinal stromal tumours (GIST) within the expanded access program (EAP) in the UK, as shown in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

Data presented at AAD 2023 underpin the potential of upadacitinib, a selective Janus kinase inhibitor, to provide long-term improvements in patient-reported outcomes (PROs; skin symptoms, sleep, and quality of life [QoL]) in individuals with moderate-to-severe atopic dermatitis (AD).

For patients with obesity and type 2 diabetes mellitus (T2DM) who are scheduled to undergo metabolic surgery, the presence of hypertension and hypercholesterolemia at baseline may predict failure of T2DM remission after the procedure, according to a study.